Cantor Fitzgerald reiterates Axsome Therapeutics stock rating, maintains price target
PositiveFinancial Markets

Cantor Fitzgerald has reaffirmed its stock rating for Axsome Therapeutics and is maintaining its price target, indicating confidence in the company's future performance.
Editor’s Note: This is significant for investors as it reflects the analysts' belief in Axsome Therapeutics' potential growth and stability in the market, which can influence investment decisions.
— Curated by the World Pulse Now AI Editorial System